This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Medical Ethics  • Cardiovascular System  • Quality of Care  • Patient Safety/ Medical Error  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Hematology/ Hematologic Malignancies  • Anemias  • Hematology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Natanson and colleagues¹ published a meta-analysis attempting to compare the safety profile for 5 different HBOCs. They pooled adverse event data for MI and death from 16 diverse trials conducted from 1997 to 2007, with study populations ranging from 10 to more than 700 patients in a variety of cardiac, orthopedic, vascular, ischemic stroke, and trauma patient populations. The majority of data came from earlier generation products, including HemAssist (Baxter Healthcare, Deerfield, Illinois) and Hemolink (Hemosol Inc, Mississauga, Ontario, Canada), which were discontinued in 1998 and in 2004, respectively; Hemopure (Biopure); and PolyHeme (Northfield Laboratories, Evanston, Illinois). The pooled analysis concluded that HBOCs were associated with a significantly increased risk of death and MI.

Among the 16 trials included in the meta-analysis by Natanson et al was a single 90-patient, phase 2 orthopedic surgery study evaluating Hemospan (Sangart, San Diego, California).² The authors incorrectly reported the . . . [Full Text of this Article]

Peter E. Keipert, PhD
pkeipert@sangart.com
Sangart Inc
San Diego, California

Christina Olofsson, MD, PhD
Department of Anesthesiology
Karolinska University Hospital
Stockholm, Sweden

Robert M. Winslow, MD
Sangart Inc

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis
Charles Natanson, Steven J. Kern, Peter Lurie, Steven M. Banks, and Sidney M. Wolfe
JAMA. 2008;299(19):2304-2312.
ABSTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Lewis J. Levien, Richard E. Hodgson, and Michael F. M. James
JAMA. 2008;300(11):1295.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Roger J. Lewis and Norman Fost
JAMA. 2008;300(11):1296.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Aryeh Shander, Mazyar Javidroozi, and Gary Thompson
JAMA. 2008;300(11):1296-1297.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Angela Sauaia, Ernest E. Moore, and Anirban Banerjee
JAMA. 2008;300(11):1297.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Babak Sarani and Vicente Gracias
JAMA. 2008;300(11):1297-1298.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Charles Natanson, Peter Lurie, and Sidney M. Wolfe
JAMA. 2008;300(11):1298-1299.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Dean Fergusson and Lauralyn McIntyre
JAMA. 2008;300(11):1299.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis
Charles Natanson, Steven J. Kern, Peter Lurie, Steven M. Banks, and Sidney M. Wolfe
JAMA. 2008;299(19):2304-2312.
ABSTRACT | FULL TEXT